Date	e:7/27/202	2	
	r Name: Zhen		
post		KI resistance: a case repor	oredicts disease progression and genotype alterations in t
relate part to trelate The	ted to the content of your name ies whose interests may be cansparency and does not notionship/activity/interest, it following questions apply t	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are one any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the manuscript of the manuscript of the manuscript. Disclosure represents a commitment of the manuscript of the manuscript of the manuscript. Disclosure represents a commitment of the manuscript of the
The to th	ne epidemiology of hyperte	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
In it	lication, even if that medica em #1 below, report all sup time frame for disclosure is	port for the work reported	d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed) Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pas	t 36 months
3	Royalties or licenses	XNone	

Consulting fees

4

X__None

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
_				
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board	· · ·		
10	Leadership or fiduciary role in other board, society,	XNone		
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X None		
	Stock of Stock options	<u>X</u>		
12	Receipt of equipment,	X None		
	materials, drugs, medical writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	ase summarize the above co	onflict of interest in the follow	owing box:	
N	lone			

Date	e:7/27/202	2	
You	r Name: Cheng	gwu Liu	
			predicts disease progression and genotype alterations in
			rt
Man	uscript number (if known):		
	• •	•	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third
	-	•	of the manuscript. Disclosure represents a commitment
-		-	If you are in doubt about whether to list a
	tionship/activity/interest, it	-	•
	following questions apply t uscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to th		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	induction, even in that incure	icion is not mentioned in	the managempt.
In it	em #1 below, report all sup	port for the work reporte	d in this manuscript without time limit. For all other items,
	time frame for disclosure is	•	a in and indicate the control of an other recities,
		and passed memorial	
		T	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate none (add rows as	institution)
		needed)	
		Time frame: Since the initi	al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	st 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X None	

4

Consulting fees

_X__None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	0,		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X_None	
12	Descript of a suitage and	V None	
12	Receipt of equipment, materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
	ase summarize the above co	nflict of interest in the fol	lowing box:

Date	e:7/27/202	2	
	Name: Senyi		
post		KI resistance: a case repo	predicts disease progression and genotype alterations in rt
relat part to tr	ted to the content of your nies whose interests may be	nanuscript. "Related" me affected by the content of ecessarily indicate a bias	I relationships/activities/interests listed below that are cans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment. If you are in doubt about whether to list a poso.
	following questions apply t uscript only.	o the author's relationsh	ips/activities/interests as they relate to the current
to th		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is	-	ed in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the init	ial planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

Consulting fees

X__None

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
_				
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board	· · ·		
10	Leadership or fiduciary role in other board, society,	XNone		
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X None		
	Stock of Stock options	<u>X</u>		
12	Receipt of equipment,	X None		
	materials, drugs, medical writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	ase summarize the above co	onflict of interest in the follow	owing box:	
N	lone			

Your	r Name: Feng	Lin				
	Nanuscript Title: Circulating tumor DNA accurately predicts disease progression and genotype alterations in ostoperative adjuvant EGFR-TKI resistance: a case report					
relat parti to tr	ted to the content of your miles whose interests may be	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias. I	relationships/activities/interests listed below that are any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so.			
	following questions apply to suscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>			
to th	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.					
	em #1 below, report all sup time frame for disclosure is	-	in this manuscript without time limit. For all other items,			
		Name all entities with	Specifications/Comments			
		whom you have this	(e.g., if payments were made to you or to your			
		relationship or indicate	institution)			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	XNone	
4	Consulting fees	X_None	

				_
_				_
5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or educational events			
-		V None		
6	Payment for expert testimony	XNone		_
	testimony			_
7	Constant for attending	V. Name		_
7	Support for attending	XNone		
	meetings and/or travel			
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			_
13	Other financial or non-	XNone		
	financial interests			
DI.			tallander han	
Pie	ase summarize the above co	milict of interest in the	ollowing box:	
Γ.				
	lone			
- 1				

Date:	7/13/22
Your Nam	e:Hatim Husain
	t Title: Circulating tumor DNA accurately predicts disease progression and genotype alterations in tive adjuvant EGFR-TKI resistance: a case report
Manuscri	t number (if known <u>):</u>
related to parties w	rest of transparency, we ask you to disclose all relationships/activities/interests listed below that are the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third ose interests may be affected by the content of the manuscript. Disclosure represents a commitment rency and does not necessarily indicate a bias. If you are in doubt about whether to list a
•	p/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastXNone	36 months
3	Royalties or licenses	XNone	
4	Consulting fees	Janssen, Astrazeneca	consulting fees

5	Payment or honoraria for	Janssen, Astrazeneca,	honoraria
	lectures, presentations,	Neogenomics, Foundation	
	speakers bureaus,	Medicine	
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
	•		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	x_None	
	pending		
9	Participation on a Data	_xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_xNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Receipt of equipment,	xNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	x None	
	financial interests		
		1	
Diaa			audea hau

Please summarize the above conflict of interest in the following box:

eceived consulting fees from Janssen and Astrazeneca and honoraria from Janssen, Astrazeneca, Foundation Medicine

Please place an "X" next to the following statement to indicate your agreement:

DISCLOSURE FORM

08/Jul/2022

ships/activities/so the content of t	parency, we ask you to disclose all (interests listed below that are if your manuscript. "Related" means any relation or-profit third may be affected by the content of the manuscript is commitment bes not necessarily indicate a bias. If you are in or list a relationship/activity/interest, it is preferable is apply to the author's (interests as they relate to the current hips/activities/interests should be defined broadly. anuscript pertains hypertension, you should declare all relationships antihypertensive medication, even if that medicate manuscript. ret all support for the work reported in this ne limit. For all other items, losure is the past 36 months. Name all entities with whom you have this relationship or indicate institution) none (add rows as needed) _None
ript number (if diesest of transpositions of the content of the c	parency, we ask you to disclose all finterests listed below that are of your manuscript. "Related" means any relation for-profit third may be affected by the content of the manuscript a commitment per not necessarily indicate a bias. If you are in a list a relationship/activity/interest, it is preferable ships/activities/interests should be defined broadly anuscript pertains hypertension, you should declare all relationships antihypertensive medication, even if that medicate manuscript. The tall support for the work reported in this ne limit. For all other items, losure is the past 36 months. Name all entities with whom you have this (e.g., if payments were made to you or to your relationship or indicate institution) none (add rows as needed) None
caterest of transpoships/activities/so the content of the content	parency, we ask you to disclose all interests listed below that are of your manuscript. "Related" means any relation or-profit third may be affected by the content of the manuscript a commitment per not necessarily indicate a bias. If you are in the polist a relationship/activity/interest, it is preferable apply to the author's interests as they relate to the current interests as they related broadly. The province is the past 36 months interests and the province interests are interested in this interest as they related interests as they related interests as they related interests as they related in the current interests as the content in the current in the current interests as the content in the current interests as the content in the current in the current in the current in the current interests as the content in the current in the current interests as the content in
ships/activities/ to the content of	Vinterests listed below that are of your manuscript. "Related" means any relation or-profit third may be affected by the content of the manuscript a commitment per not necessarily indicate a bias. If you are in the polist a relationship/activity/interest, it is preferable is apply to the author's vinterests as they relate to the current pertains hypertension, you should declare all relationships antihypertensive medication, even if that medicate manuscript. The tall support for the work reported in this ne limit. For all other items, losure is the past 36 months. Name all entities with whom you have this relationship or indicate institution) none (add rows as needed) None
ships/activities/ cipt only. hor's relationsh nple, if your m oidemiology of l nufacturers of entioned in the #1 below, repor ript without tin frame for discl	interests as they relate to the current hips/activities/interests should be defined broadly. anuscript pertains hypertension, you should declare all relationships antihypertensive medication, even if that medicate manuscript. It all support for the work reported in this ne limit. For all other items, losure is the past 36 months. Name all entities with whom you have this relationship or indicate institution) none (add rows as needed) None
anple, if your modemiology of landacturers of entioned in the landacturers of entioned landacturers of e	hypertension, you should declare all relationships antihypertensive medication, even if that medicate manuscript. It all support for the work reported in this ne limit. For all other items, losure is the past 36 months. Name all entities with whom you have this relationship or indicate institution) none (add rows as needed) None
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	Name all entities with whom you have this relationship or indicate institution) none (add rows as needed) Name all entities with whom you have this relationship or indicate institution) Name all entities with whom you have this relationship or indicate institution) Name all entities with whom you have this relationship or indicate institution) Name all entities with whom you have this relationship or indicate institution) None
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you have this (e.g., if payments were made to you or to your relationship or indicate institution) none (add rows as needed) None
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	None
Grants or contracts from any entity (if not indicated in item #1 above).	
Royalties or licenses	None
Consulting fees	None
Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None
Payment for expert restimony	None
Support for attending meetings and/or travel	None
Patents planned, issued or pending	None
Participation on a Data Safety Monitoring Board or Advisory Board	None
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
Stock or stock options	None
Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
Other financial or non- financial interests	None
	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses Consulting fees Consulting fees Consulting fees Consulting fees Consulting fees Cayment or honoraria for ectures, presentations, speakers bureaus, manuscript writing or educational events Cayment for expert estimony Cayment for attending meetings and/or travel Catents planned, issued or bending Catents planned, issued

Please place an "X" next to the following statement to indicate your agreement:

Date	e:7/27/202	.2	
	r Name: Lunxı		
post		KI resistance: a case repo	predicts disease progression and genotype alterations in rt
rela part to to	ted to the content of your n ies whose interests may be	nanuscript. "Related" me affected by the content o ecessarily indicate a bias.	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a poso.
	following questions apply touscript only.	o the author's relationshi	ips/activities/interests as they relate to the current
to th	•	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is	•	ed in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	ial planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

Consulting fees

X__None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	V. Nana	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12 Rec	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
D I		. Clt. 1 . C t. 1 t	alla de la la
Plea	ise summarize the above co	intlict of interest in the f	ollowing box:
	lono		
	lone		